ImmuCell Announces Full Year 2015 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ImmuCell Announces Full Year 2015 Financial Results

PORTLAND, ME --(Marketwired - February 10, 2016) - ImmuCell Corporation ( NASDAQ : ICCC ), a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, today announced financial results for its fourth quarter and year ended December 31, 2015.

2015 Fourth Quarter Financial Overview:

  • Total sales increased 22% to $2.7 million compared to fourth quarter 2014;
  • 14 th consecutive quarter of positive sales growth and 20 th quarter of positive sales growth out of the last 21 quarters (in comparison to the same quarters of the prior years); and
  • Net income of $289,000, or $0.09 per diluted share, during fourth quarter 2015 compared to net income of $131,000, or $0.04 per diluted share, during fourth quarter 2014.

2015 Full Year Financial Overview:

  • Total sales increased 35% to $10.2 million compared to 2014;
  • First Defense ® sales increased 36%, or $2.5 million, compared to 2014;
  • Net income of $1.2 million, or $0.38 per diluted share, during 2015 in contrast to net loss of ($167,000), or ($0.06) per share, during 2014;
  • Net cash provided by operating activities of $2.9 million during 2015 in comparison to $302,000 during 2014; and
  • Cash, cash equivalents, short-term investments and long-term investments of $6.5 million as of December 31, 2015 compared to $3.8 million as of December 31, 2014.

Management's Discussion: "We continue to execute on the two core components of our business strategy," commented Michael F. Brigham, president and chief executive officer. "First, we are expanding the market penetration of First Defense ® , our best-in-class treatment for calf scours. As evidenced by the 36% increase in year-over-year First Defense ® sales, our sales and marketing team is doing an effective job introducing the product to new customers and communicating how it provides Immediate Immunity ™ to newborn calves, generating a dependable return on investment to dairy and beef producers. We look forward to regulatory approval in 2017 for the addition of a bovine rotavirus disease claim to our existing claims against E. coli and coronavirus infections. That would enable us to bring the first passive antibody product with this breadth of disease claims to market. Second, we are advancing the development of Mast Out ® , our novel treatment for subclinical mastitis in lactating dairy cows. Our groundbreaking product innovation is unlike all other mastitis treatments on the market today that are all sold subject to a milk discard period. Our goal is to revolutionize the way mastitis is treated by making treatment of subclinical infections economically feasible by not requiring a milk discard or meat withhold during, or for a period of time after, treatment. No other product presently on the market can offer this value proposition."

Other Financial Results for 2015:

Total product sales during the three-month period ended December 31, 2015 increased by 22%, or $489,000, to $2.7 million from $2.2 million during the same period in 2014. Total product sales during the year ended December 31, 2015 increased by 35%, or $2.6 million, to $10.2 million from $7.6 million during the same period in 2014. 

Sales of First Defense ® and related product line extensions increased by 36% during the year ended December 31, 2015, in comparison to 2014. Sales also benefited from a strong beef price and from the temporarily interrupted supply to the market of a competitive product during late 2014 and early 2015. This new level of sales demand has exceeded the Company's current production capacity and available inventory, resulting in a backlog of First Defense ® orders aggregating approximately $381,000 as of December 31, 2015. The investment to increase liquid processing production capacity for First Defense ® by 50% was completed during fourth quarter 2015. The investment to increase freeze-drying production capacity for First Defense ® by 100% is proceeding on schedule and is expected to be completed before the end of first quarter 2016.

Product development expenses decreased by 28%, or $132,000, to $331,000 during the fourth quarter of 2015, as compared to $463,000 during the same period in 2014, aggregating 12% and 21% of product sales during the fourth quarters of 2015 and 2014, respectively. Product development expenses decreased by 43%, or $944,000, to $1.2 million during the year ended December 31, 2015, as compared to $2.2 million during the same period in 2014, aggregating 12% and 29% of product sales during 2015 and 2014, respectively. The higher expenses during the full year of 2014 were largely the result of expenses incurred in connection with the Company's small-scale Nisin production plant investment.

Income before income taxes was approximately $430,000 during the fourth quarter of 2015 in comparison to income before income taxes of $188,000 during the same period in 2014. Net income was $289,000, or $0.09 per diluted share, during the fourth quarter of 2015 in comparison to net income of $131,000, or $0.04 per diluted share, during the same period in 2014.

Income before income taxes was approximately $2.1 million during the year ended December 31, 2015 in contrast to a loss before income taxes of ($255,000) during the same period in 2014. Net income was $1.2 million, or $0.38 per diluted share, during the year ended December 31, 2015 in contrast to net loss of ($167,000), or ($0.06) per share, during the same period in 2014.

Financing Milestones:

  • A commitment letter with TDBank N.A. covering a $4.3 million credit facility (which is subject to customary closing conditions) was signed on January 19, 2016; and
  • Gross proceeds from an underwritten public offering of 1,123,810 shares of common stock at a price to the public of $5.25 per share that closed on February 3, 2016 were $5.9 million; Net proceeds from the common stock issuance were $5.3 million, after deducting underwriting discounts and other expenses incurred in connection with the issuance.

"Our current cash, plus our cash flow from operations, together with the new capital raised provides a road map to complete the development of Mast Out ® and bring the product to market," further commented Michael F. Brigham, president and chief executive officer. "Sales of First Defense ® have funded most of the product development to date. This new funding will be used to construct and equip a facility to produce Nisin, the active ingredient in Mast Out ® . Our preliminary estimate for this project is approximately $17 to $18 million, and we aim to complete the construction and installation work in late 2017 or 2018. This would keep us on our expected timeline for achieving FDA approval in late 2018 or 2019. This is an important milestone in the history of ImmuCell. We look forward with great anticipation."

Conference Call Interested parties can access the conference call by dialing (844) 855-9502 or (412) 317-5499 at 4:30 PM ET today. A live Internet webcast will be available at https://www.webcaster4.com/Webcast/Page/1214/13295 . 

A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation #10080723. A webcast replay will be available for 90 days at the same internet address above.

About ImmuCell ImmuCell Corporation's ( NASDAQ : ICCC ) purpose is to create scientifically-proven and practical products that improve animal health and productivity in the dairy and beef industries. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company has also developed products that address mastitis, the most significant cause of economic loss to the dairy industry. Press releases and other information about the Company are available at: ( http://www.immucell.com ).

   
   
Condensed Statements of Operations  
           
    For the Three-Month Periods Ended December 31,   For the Years Ended December 31,  
(In thousands, except per share amounts)   2015   2014   2015   2014  
                           
Product sales   $ 2,694   $ 2,205   $ 10,229   $ 7,597  
Cost of goods sold     1,037     862     3,978     3,148  
  Gross margin     1,657     1,343     6,251     4,449  
                           
Sales, marketing and administrative expenses     865     681     2,894     2,476  
Product development expenses     331     463     1,235     2,179  
  Operating expenses     1,196     1,144     4,129     4,655  
                           
NET OPERATING INCOME (LOSS)     461     199     2,122     (206 )
                           
Other expenses, net     31     10     59     49  
                           
INCOME (LOSS) BEFORE INCOME TAXES     430     189     2,063     (255 )
                           
Income tax expense (benefit)     141     58     850     (88 )
                           
NET INCOME (LOSS)   $ 289   $ 131   $ 1,213     ($167 )
                           
Weighted average common shares outstanding:                          
  Basic     3,055     3,027     3,042     3,027  
  Diluted     3,175     3,109     3,166     3,027  
                           
NET INCOME (LOSS) PER SHARE:                          
  Basic   $ 0.09   $ 0.04   $ 0.40     ($0.06 )
  Diluted   $ 0.09   $ 0.04   $ 0.38     ($0.06 )
                           
                           
Selected Balance Sheet Data
         
         
    As of   December 31, 2015   As of  December 31, 2014
(In thousands)            
Cash, cash equivalents, short-term and long-term investments   $ 6,524   $ 3,835
Net working capital     7,056     4,460
Total assets     14,601     11,052
Stockholders' equity   $ 10,614   $ 9,258
             

Safe Harbor Statement: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future financial performance; the scope and timing of future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated by products still in development; future sources of financial support for our product development, manufacturing and marketing efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of a facility to produce the Drug Substance (active pharmaceutical ingredient) for Mast Out ® ; the timing and outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets; costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the facility to produce the Drug Substance for Mast Out ® ; factors that may affect the dairy and beef industries and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy of our understanding of our distributors' ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies; anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", "projects", "forecasts" and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes in laws and regulations, decision making by regulatory authorities, possible dilutive impacts on existing stockholders from any equity financing transactions in which we may engage, currency fluctuations and other risks detailed from time to time in filings we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially due to various factors, including the risk factors summarized in our quarterly filings with the SEC and uncertainties otherwise referred to in this press release.

Contact:  Michael F. Brigham President and CEO ImmuCell Corporation (207) 878-2770 Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 15

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 94

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 107

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
BLLN Faces Fresh Questions After Short-Seller Report

Updated Category News Views 106

A six-percent air pocket is one thing; a disclosure mismatch is another beast entirely. BillionToOne shares fell on November 18 after short-seller Fuzzy Panda Research alleged the company had not disclosed meaningful regulatory scrutiny, including an alleged Tennessee matter in which regulators suspected fraud in 2024. That is an allegation from a short seller, not a...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 98

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Unite: Taking Action Against aTyr Pharma's Misconduct

Updated Category News Views 142

Understanding the Case Against aTyr Pharma, Inc. Many investors have faced uncertainty in recent years, particularly in the healthcare sector. aTyr Pharma, Inc. (NASDAQ: ATYR) finds itself at the center of a securities fraud lawsuit, directed by the Schall Law Firm, designed to or encourage investors who may have been adversely impacted by the company's actions to take a...

Continue Reading
BIC Announces Rob Versloot as New CEO for Future Growth

Updated Category News Views 1055

Exciting Leadership Transition at BIC BIC has recently made a significant leadership transition by appointing Rob Versloot as the new Chief Executive Officer. This shift follows an extensive selection process conducted with utmost diligence and care by the Succession Committee under the guidance of Edouard Bich, the Chair of the Board of Directors. Background on Rob...

Continue Reading
Canadian Market Sees Gains as S&P/TSX Composite Hits Records

Updated Category News Views 167

Overview of the Canadian Stock Market Recently, the Canadian stock market has shown significant progress, culminating in a positive trading session that reflected growing investor confidence. The S&P/TSX Composite Index closed the day up by 0.40%, showcasing lively market activity and enthusiasm across various sectors. Sector Performances Fueling Market Gains Key sectors...

Continue Reading
Three Risky Consumer Staples That Might Struggle Soon

Updated Category News Views 153

Overview of Consumer Staples at Risk As recent market analysis highlights, several stocks in the consumer staples sector may be indicating potential challenges that investors should take into account. While consumer staples are generally viewed as safer investments, certain indicators suggest that this perception may not hold for every stock, especially in the current...

Continue Reading
Healthcare IT Outsourcing Market Projected to Reach $122.72 Billion

Updated Category News Views 156

Understanding the Surge in Healthcare IT Outsourcing The Healthcare IT Outsourcing Market signifies a booming ecosystem, anticipated to reach USD 122.72 billion by 2032, with a notable compound annual growth rate (CAGR) of 7.44%. The driving forces behind this remarkable growth are rooted in digital transformation and an increasing demand for operational efficiency....

Continue Reading